 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- emerfetamab (AMG 673) / Amgen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 20, 2021
P1, N=46, Terminated, Sponsor: Amgen
N=95 --> 46 | Trial completion date: Mar 2022 --> Dec 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2022 --> Dec 2020; Priortization of other Programs
- eluvixtamab (AMG 330) / Amgen, AMG 673 / Amgen
CD33 BiTE® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3855;
They support the notion that T cell co-signaling receptors like CD86 and PD-L1 modulate T-cell response in an early event manner. Prospective analyses in clinical trials are needed to validate the relevance of checkpoint molecule expression on target cells as a potential predictive biomarker for response.
- || emerfetamab (AMG 673) / Amgen
Trial completion date, Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 27, 2021
P1, N=95, Active, not recruiting, Sponsor: Amgen
Prospective analyses in clinical trials are needed to validate the relevance of checkpoint molecule expression on target cells as a potential predictive biomarker for response. Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- AMG 673 / Amgen
[VIRTUAL] Updated results from phase 1 dose escalation study of AMG 673, a bispecific T-cell engager molecule, in R/R AML patients (Track 8) - Mar 2, 2021 - Abstract #JSMO2021JSMO_853;
- || emerfetamab (AMG 673) / Amgen
Enrollment closed: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jan 12, 2021
P1, N=95, Active, not recruiting, Sponsor: Amgen
Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Recruiting --> Active, not recruiting
- || emerfetamab (AMG 673) / Amgen
Enrollment change, Trial completion date, Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 23, 2020
P1, N=95, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting N=50 --> 95 | Trial completion date: Oct 2022 --> Oct 2021 | Trial primary completion date: Oct 2022 --> Oct 2021
- AMG 673 / Amgen
[VIRTUAL] UPDATED RESULTS FROM A PHASE 1 FIRST-IN-HUMAN DOSE ESCALATION STUDY OF AMG 673, A NOVEL ANTI-CD33/CD3 BITE® (BISPECIFIC T-CELL ENGAGER) IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA () - May 16, 2020 - Abstract #EHA2020EHA_781;
P1
Preliminary assessment shows an acceptable safety profile with evidence of anti-leukemic activity. These results support schedule optimization and further dose escalation of AMG 673 in patients with R/R AML.
- AMG 673 / Amgen
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Chapin Theater (W320), Level 3 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5138;
P1
An association was observed between PK/PD relationships that were consistent with the biological activity of AMG 673 . These preliminary results support further dose escalation of the AMG 673 HLE BiTE® molecule in patients with R/R AML.
- DARTS, Bites and ADCs for the Treatment of AML and for Conditioning for Allogeneic Stem Cell Transplantation () - Sep 26, 2019 - Abstract #SOHO2019SOHO_275;
Additional correlative studies will be presented for this and other AML bispecifics currently being tested by our and other groups in the clinic. Finally, we will present data on the use of ADCs for the treatment of AML in vitro and for conditioning for stem cell transplantation within and across MHC barriers using mouse preclinical transplant models.
- | emerfetamab (AMG 673) / Amgen
Trial completion date, Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 19, 2019
P1, N=50, Recruiting, Sponsor: Amgen
Finally, we will present data on the use of ADCs for the treatment of AML in vitro and for conditioning for stem cell transplantation within and across MHC barriers using mouse preclinical transplant models. Trial completion date: Mar 2020 --> Oct 2022 | Trial primary completion date: Mar 2020 --> Aug 2022
- | emerfetamab (AMG 673) / Amgen
Trial completion date, Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 4, 2018
P1, N=50, Recruiting, Sponsor: Amgen
Trial completion date: Mar 2020 --> Oct 2022 | Trial primary completion date: Mar 2020 --> Aug 2022 Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
- emerfetamab (AMG 673) / Amgen
Trial primary completion date: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 7, 2017
P1, N=50, Recruiting, Sponsor: Amgen
Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020 Trial primary completion date: Jul 2019 --> Jul 2020
- |||||| emerfetamab (AMG 673) / Amgen
Enrollment open: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Sep 28, 2017
P, N=50, Recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2019 --> Jul 2020 Not yet recruiting --> Recruiting